Drug Trial Radar · NCT00949351
Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy
Last checked: Nov 20, 2026Latest source record: Jul 30, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 2009
Primary completion
Jul 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- Lerdsin General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 30, 2009
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 30 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Activation of renin-angiotensin plays a crucial role diabetic nephropathy. Angiotensin converting enzyme inhibitor (ACEI) and Angiotensin I receptor blocker (ARB) has been shown renoprotection whether it was used alone or in combination. Aliskiren is a direct renin inhibitor (DRI) that has shown renal benefits and safety when combined with ARB. However, to date, the safety of add on aliskiren to the combination treatment of ACEI and ARB in diabetic nephropathy patients remains to elucidate.
Conditions
- Type 2 Diabetes With Nephropathy
Interventions
Aliskiren 300mg/dDrug
Aliskiren 300mg/d v.s. placebo for 12wk
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess short-term safety of the combination of aliskiren 300 mg/valsartan 160 mg /enalapril 20 mg in patients with diabetic nephropathyTime frame: 12 wk after randomization
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lerdsin General Hospital
Bangkok, Thailand
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.